Patents by Inventor Michael P. Belmares
Michael P. Belmares has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9611315Abstract: The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.Type: GrantFiled: June 20, 2014Date of Patent: April 4, 2017Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Jonathan David Garman, Michael P. Belmares, Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer
-
Patent number: 9365620Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: May 9, 2014Date of Patent: June 14, 2016Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 9061070Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: GrantFiled: September 14, 2012Date of Patent: June 23, 2015Assignee: NoNO, Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20150093742Abstract: The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.Type: ApplicationFiled: June 20, 2014Publication date: April 2, 2015Inventors: Peter S. Lu, Jonathan David Garman, Michael P. Belmares, Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer
-
Publication number: 20150018283Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: ApplicationFiled: May 9, 2014Publication date: January 15, 2015Applicant: NoNO NC.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8748387Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: November 13, 2012Date of Patent: June 10, 2014Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8633160Abstract: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.Type: GrantFiled: July 3, 2008Date of Patent: January 21, 2014Assignee: Nono Inc.Inventors: Michael P. Belmares, Kenneth A. Mendoza, Peter S. Lu, David Garman, Michael Tymianski
-
Patent number: 8536129Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.Type: GrantFiled: July 19, 2011Date of Patent: September 17, 2013Assignee: NoNO Inc.Inventors: Andrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
-
Publication number: 20130172230Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicants: Arbor Vita Corporation, NoNo Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8324168Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: September 3, 2009Date of Patent: December 4, 2012Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8288345Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: GrantFiled: February 29, 2008Date of Patent: October 16, 2012Assignee: Nono, Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20120258890Abstract: The present application describes methods for assessing influenza infection, including prognosis. An assay that determines the amount of the NS1 and NP proteins of influenza virus shows enhanced sensitivity and reliability compared to either antigen alone. Many formats employ pan-specific antibodies (i.e., that react with all or at least with multiple strains within an influenza type).Type: ApplicationFiled: April 4, 2012Publication date: October 11, 2012Applicant: ARBOR VITA CORPORATIONInventors: PETER S. LU, MICHAEL P. BELMARES, CAROL TAN, LINDA MCALLISTER
-
Publication number: 20120164629Abstract: The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.Type: ApplicationFiled: February 2, 2012Publication date: June 28, 2012Inventors: Peter Lu, Jonathan David Garman, Michael P. Belmares, Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer
-
Patent number: 8163474Abstract: The present application describes methods for assessing influenza infection, including prognosis. An assay that determines the amount of the NS1 and NP proteins of influenza virus shows enhanced sensitivity and reliability compared to either antigen alone. Many formats employ pan-specific antibodies (i.e., that react with all or at least with multiple strains within an influenza type).Type: GrantFiled: March 16, 2009Date of Patent: April 24, 2012Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Michael P. Belmares, Carol Tan, Linda McAllister
-
Publication number: 20120083449Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.Type: ApplicationFiled: July 19, 2011Publication date: April 5, 2012Applicants: Arbor Vita Corporation, NoNO Inc.Inventors: Andrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
-
Publication number: 20120052484Abstract: The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.Type: ApplicationFiled: August 18, 2011Publication date: March 1, 2012Inventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento, Michael P. Belmares
-
Patent number: 8048676Abstract: The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.Type: GrantFiled: January 5, 2007Date of Patent: November 1, 2011Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento, Michael P. Belmares
-
Patent number: 8008253Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.Type: GrantFiled: July 1, 2008Date of Patent: August 30, 2011Inventors: Andrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
-
Patent number: 7972774Abstract: The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.Type: GrantFiled: July 27, 2007Date of Patent: July 5, 2011Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento, Michael P. Belmares
-
Patent number: 7919584Abstract: This invention relates to methods of reducing inflammatory effects in mammalian cells by treatment with compounds that interfere with calcium activated chloride channel function. The invention discloses methods of treating these disorders by administering inhibitors that disrupt protein-protein interactions involved in these disorders, screening methods to identify such inhibitors and specific compositions useful for treating these disorders.Type: GrantFiled: April 14, 2006Date of Patent: April 5, 2011Assignee: Arbor Vita CorporationInventors: Michael P. Belmares, Dave Garman